128 related articles for article (PubMed ID: 19318306)
1. [Adjuvant breast cancer treatment with hormono-radiotherapy].
Azria D; Jacot W; Gligorov J; Belkacémi Y; Zaman K; Romieu G; Ozsahin M
Bull Cancer; 2009 Mar; 96(3):285-9. PubMed ID: 19318306
[TBL] [Abstract][Full Text] [Related]
2. [How to combine hormonotherapy and radiation treatment in adjuvant breast cancer?].
Azria D; Ozsahin M; Gligorov J; Zaman K; Llacer Moscardo C; Lemanski C; Jacot W; Belkacémi Y
Cancer Radiother; 2008 Jan; 12(1):37-41. PubMed ID: 18248833
[TBL] [Abstract][Full Text] [Related]
3. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
4. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
Gori S; Anastasi P; Marrocolo F
Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
[No Abstract] [Full Text] [Related]
5. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
6. [Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
Fodor J
Orv Hetil; 2006 Jan; 147(3):121-5. PubMed ID: 16515031
[TBL] [Abstract][Full Text] [Related]
7. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
[TBL] [Abstract][Full Text] [Related]
9. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
11. Letrozole in breast cancer.
Shahab N
N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
[No Abstract] [Full Text] [Related]
12. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
[TBL] [Abstract][Full Text] [Related]
13. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
14. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant aromatase inhibitors: are we there yet?
Fleming GF
Cancer; 2003 Nov; 98(9):1779-81. PubMed ID: 14584057
[No Abstract] [Full Text] [Related]
16. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
17. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
Forciniti S
Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]